Nachrichten zur ASTRAZENECA DL-,25 SP.ADR Aktie

Puma (PBYI) Q2 Revenue Rises 11%

Key PointsNon-GAAP EPS was $0.15, beating the non-GAAP estimate of $0.09 and turning positive on a GAAP basis from a…

Arcutis (ARQT) Q2 Revenue Soars 164%

Key PointsRevenue (GAAP) soared 164% year over year to $81.5 million, surpassing analyst estimates by $7.81 million (GAAP).Net loss per…

Proactive weekly health highlights: AstraZeneca, GSK, hVIVO, Avacta, and more

…

Total Voting Rights

1 August 2025 Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…

Kimberly-Clark, Hims & Hers Health, CNH Industrial

U.S. stock index futures extended losses on Friday after a weaker-than-expected July jobs report elevated concerns about the health of…

Ionis (IONS) Q2 Revenue Soars 101%

Key PointsIonis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide…

FIVE at FIVE: BAE, Taylor Wimpey, Arkle, Cornish Metal, AstraZeneca

Its that time again ... so, lets take a look at five pieces of content worth digging into deeper this…

Stocks Halt Rally as Bond Yields Fall Ahead of Fed Decision | The Close 7/29/2025

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after…

US Expansion Not Driven By Tariffs: AstraZeneca CFO

Aradhana Sarin, AstraZeneca CFO, says the company is making a significant commitment to the U.S., explaining that the majority of…

AstraZenecas US Investment, Future of Psychedelic Therapy | Bloomberg Businessweek Daily 7/29/2025

On todays episode of Bloomberg Businessweek Daily with Tim Stenovec and Carol Massar, Pascal Soriot, Chief Executive Officer of AstraZeneca…

Why value investing has worked better outside the US

Morningstar‘s US growth index is dominated by the “ Magnificent Seven.” But internationally, the scale is far smaller. There…

FIVE AT FIVE: Drugs, banks and sausage rolls... and why the Footsie faltered in the final furlong

From pharma giants to sausage rolls, it was a day of upbeat numbers and market milestones. AstraZeneca soared, Barclays delivered…

AstraZeneca CEO: If you manufacture locally, theres no need to increase prices

CNBCs Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the companys most recent quarter, investment in innovation in…

The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk

TEM surges 91.8% YTD on rapid AI-healthcare growth, while NVDA fuels the sector with cutting-edge infrastructure and partnerships.…

AstraZeneca CEO doubles down on U.S. amid rumors of listing shift

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was…

JEFFERIES stuft ASTRAZENECA auf Hold

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca nach Zahlen auf "Hold" mit einem Kursziel…

AstraZeneca tops expectations on robust drug sales, US demand

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines…

AstraZeneca beats profit expectations on robust drug sales, U.S. demand

AstraZeneca beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand in the…

Pharmahersteller Astrazeneca wächst im zweiten Quartal überraschend stark

CAMBRIDGE (dpa-AFX) - Gute Geschäfte mit seinen Impfstoffen und Krebsmedikamenten haben den Pharmakonzern Astrazeneca im zweiten Quartal unerwartet viel…

AstraZeneca trumps Q2 forecasts, keeps outlook amid pricing, trade pressures By Investing.com

AstraZeneca trumps Q2 forecasts, keeps outlook amid pricing, trade pressures…

AstraZeneca beats second-quarter profit expectations, maintains outlook

AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but…

H1 and Q2 2025 results

29 July 2025 AstraZeneca results: H1 and Q2 2025 Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date Revenue and…

FTSE 100 LIVE: London index dips negative, Lloyds Bank and BT Group among fallers

FTSE 100 dips negative Lloyds Bank and BT Group among fallers Rolls-Royce and AstraZeneca in positive ground US-EU deal better…

Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors

In the most recent trading session, Astrazeneca (AZN) closed at $72.66, indicating a -1.38% shift from the previous trading day.…

Astrazeneca investing in multi-billion dollar facility in Virginia

It’s the most money the company has ever invested in a single manufacturing site.…

AstraZeneca investing $50B in US, Trump calls it an ‘honor’

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump administration claiming some…

Why is AstraZeneca is Investing $50bn into the US?

AstraZeneca is investing heavily in US facilities to counteract tariff impacts, planning substantial growth through local manufacturing by 2030…

AstraZeneca to invest $50B in US to boost drug manufacturing and R&D

AstraZeneca PLC (LSE:AZN) has announced plans to invest $50 billion in the United States by 2030, marking the pharmaceutical giant’s…

AstraZeneca announces $50 billion US investment in manufacturing and R&D By Investing.com

AstraZeneca announces $50 billion US investment in manufacturing and R&D…

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom…

AstraZeneca announces $50 billion U.S. investment

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing site in Virginia.…

Pharmaindustrie: AstraZeneca investiert 50 Milliarden Dollar in US-Produktion

Der schwedisch-britische Pharmakonzern AstraZeneca kündigt Milliarden-Investitionen in den USA an – und macht dabei kein Geheimnis daraus, dass Zeitpunkt und…

AstraZeneca plans to invest $50B in U.S. by 2030

…

AstraZeneca unveils $50 billion US investment as pharma tariff threat looms

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on…

AstraZeneca announces $50 billion U.S. manufacturing investment, matching its big pharma peers

AstraZeneca announces largest ever investment in U.S. manufacturing…

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.…

AstraZenecas AL Amyloidosis Drug Misses Goal in Late-Stage Studies

AZNs anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.…

AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study By Reuters

AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study…

AstraZeneca drug fails main goal of late-stage amyloidosis study

AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for…

UBS stuft ASTRAZENECA auf Buy

ZÜRICH (dpa-AFX Analyser) - Die schweizerische Großbank UBS hat Astrazeneca auf "Buy" mit einem Kursziel von 14200 Pence belassen. In…

AKTIE IM FOKUS: Daten zu Baxdrostat helfen AstraZeneca aufwärts

LONDON (dpa-AFX Broker) - Positive Studiendaten zu einem Medikament von Astrazeneca sind am Montag an der Londoner Börse gut…

AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead

Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts…

AZNs Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.…

AstraZeneca-Aktie: AstraZeneca verhandelt Milliardendeal mit Summit Therapeutics

Der britische Pharmakonzern spreche derzeit mit Summit Therapeutics über eine Vereinbarung, in deren Rahmen AstraZeneca über mehrere Jahre bis zu…

Summit, AstraZeneca in talks over $15 billion partnership deal, Bloomberg News reports

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported on Thursday,…